TaiGen Biotechnology is a dynamic player in the biopharmaceutical industry, focusing on the development and commercialization of innovative drugs. The company operates primarily in the healthcare and pharmaceutical markets, targeting both local and international clients. TaiGen's clientele includes hospitals, clinics, and healthcare providers who are in need of advanced medical treatments and therapies.

The business model of TaiGen Biotechnology revolves around research and development (R&D) of new drugs, followed by the commercialization of these drugs through partnerships and direct sales. The company invests heavily in R&D to create proprietary drugs that address unmet medical needs, particularly in the areas of infectious diseases, cancer, and other critical health conditions. Once a drug is developed and approved, TaiGen either markets it directly or licenses it to other pharmaceutical companies, generating revenue through sales and licensing fees.

TaiGen makes money by selling its developed drugs to healthcare providers and through licensing agreements with other pharmaceutical companies. These licensing agreements often include upfront payments, milestone payments (payments made when certain goals are achieved), and royalties (a percentage of sales). Additionally, TaiGen may enter into strategic partnerships and collaborations to co-develop and co-market drugs, further diversifying its revenue streams.

In summary, TaiGen Biotechnology is a biopharmaceutical company dedicated to developing and commercializing innovative drugs, serving healthcare providers in the global market. The company generates revenue through direct sales, licensing agreements, and strategic partnerships.

Keywords: Biopharmaceutical, R&D, Innovative Drugs, Healthcare, Infectious Diseases, Cancer, Licensing, Partnerships, Revenue, Commercialization.